Dimerix shares plunged 35–40% amid heavy selling and uncertainty around clinical updates, worsened by weak biotech sentiment. Further downside depends on results and the funding outlook, though volatility in early-stage biotech stocks suggests a potential for sharp rebounds.
Lumos Diagnostics shares have dropped sharply after last year’s rally, with weak technical signals and dilution concerns weighing on sentiment. Despite long-term optimism around FebriDx and US commercialisation, investors remain cautious due to slow revenue growth and ongoing funding pressures.
Neurizon Therapeutics (ASX: NUZ) is a clinical-stage biotech developing NUZ-001 for ALS and other neurodegenerative diseases. Despite promising data and global trials, the stock faces pressure from clinical delays, dilution, rising losses, and ongoing uncertainty typical of pre-revenue biotech companies.
In the current markets, even major players listed on the S&P/ASX 200 aren’t immune to caution flags on the charts. In this article, we'll examine three ASX-listed stocks whose price action suggests further downside may be ahead. We’ll look beyond the fundamentals and focus on technical signals: breakdowns below key moving averages, chart patterns like lower highs or descending triangles, and weakening momentum indicators.
.webp&w=828&q=75)
Markets faced a “soft-landing but sticky” backdrop: growth held up, yet inflation and policy uncertainty kept risk elevated and dispersion high. The US stayed resilient but uneven as labour demand cooled and the Fed remained cautious. The ECB stayed meeting-by-meeting. Australia felt higher-for-longer, rotating into defensives.
The global macroeconomic backdrop shifted notably in the week ending 28 November 2025, fuelling a renewed "risk-on" sentiment that propelled a decisive recovery in Australian equities. In the United States, softening labour market indicators—specifically an acceleration in weekly ADP job losses—combined with a cooler-than-expected Core PPI reading and dovish commentary from Federal Reserve officials, led to a sharp repricing of interest rate expectations, with markets now pricing in an ~85% probability of a December cut. This pivot abroad overshadowed sticky domestic inflation data, allowing interest-rate-sensitive growth sectors to lead the S&P/ASX 200 higher, even as uncertainty persists around the Reserve Bank of Australia’s policy path.
...
